Fenretinide

CAT: 0804-HY-15373-01Size: 5 mgDry Ice: NoHazardous: No
CAT#: HY-15373-01Size: 5 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.
CAS Number
[65646-68-6]
Product Name Alternative
4-HPR; ISLA-101
UNSPSC
12352005
Hazard Statement
H302+H312+H332, H315, H319, H335, H360
Target
Autophagy; RAR/RXR
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Fenretinide.html
Purity
99.15
Solubility
DMSO : ≥ 100 mg/mL
Smiles
CC(/C=C/C=C(/C=C/C1=C(CCCC(C)1C)C)C)=C\C(NC2=CC=C(O)C=C2)=O
Molecular Formula
C26H33NO2
Molecular Weight
391.55
Precautions
H302+H312+H332, H315, H319, H335, H360
References & Citations
[1]Apraiz, Aintzane., et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochemistry and Cell Biology (2012), 90 (2), 209-223.|[2]Bikman, Benjamin T., et al. Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide Biosynthesis. Journal of Biological Chemistry (2012), 287 (21), 17426-17437.|[3]Cooper JP, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011 Jul;163 (6) :1263-75.|[4]Golubkov V, et al. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005 Jan-Feb;25 (1A) :249-53.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName